Bill > S526

This bill, called the Pharmacy Benefit Manager Transparency Act of 2025, aims to prevent unfair and deceptive practices in pharmacy benefit management (PBM) services. The legislation prohibits pharmacy benefit managers from engaging in several anti-competitive practices, such as charging health plans different amounts for prescription drugs than they reimburse pharmacies, arbitrarily reducing reimbursement payments, or increasing fees to offset government-mandated reimbursement changes. The bill requires PBMs to fully disclose all costs, fees, and remuneration received from drug manufacturers, and mandates annual reporting to federal agencies about their pricing and formulary practices. It also establishes whistleblower protections for individuals who report potential violations and provides enforcement mechanisms through the Federal Trade Commission and state attorneys general, with potential civil penalties up to $1 million for violations. Additionally, the bill requires a comprehensive study by the Government Accountability Office to examine the role of PBMs in the pharmaceutical supply chain, their market competition, and the impact of their business practices on drug costs. The legislation is designed to increase transparency, reduce potential conflicts of interest, and ultimately lower prescription drug costs for consumers by introducing more oversight into the pharmacy benefit management industry.

Transportation and Infrastructure

https://www.congress.gov/bill/119th-congress/senate-bill/526/all-info